C4 Therapeutics presents cemsidomide biomarker data at IMS Annual MeetingSep 25Clinical readoutC4 Therapeutics, Inc.cemsidomide
BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screeningSep 25Weekly roundup, 4 itemsBristol Myers Squibbclarithromycin
Roche posts HCC trial results, registers five new studies across cancer, MS, flu, COPDSep 18Weekly roundup, 6 itemsbaloxavir marboxilcevostamab
Quince Therapeutics sells Italian unit and A-T drug technology to Ayma for $450,000Sep 14M&AQuince Therapeutics, Inc.
FDA approves Ionis's ZANVASTRO for Alexander diseaseSep 4Regulatory milestoneIonis Pharmaceuticalszilganersen
UCSD registers Phase 2 study of low-dose dexamethasone to prevent Immunocore's tebentafusp CRSSep 3Trial updatedexamethasoneImmunocore Ltd
AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosisAug 28Trial updateAbbViedexamethasone
Cellectar registers Phase 3 trial comparing iopofosine I 131 to R-CD in Waldenstrom'sAug 14Trial updateCellectar Biosciences, Inc.
Cellectar reports Q2 2026 results, advances Phase 3 WM trial toward mid-2027 filingAug 13Quarterly updateCellectar Biosciences, Inc.
C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 dataAug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide
GSK-linked trials: six new registrations this week, all not yet recruitingAug 6Weekly roundup, 6 itemsaletekitugbelantamab
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meetingAug 3Quarterly updateOcular Therapeutix, Inc.
Oculis posts terminated Phase 3 OCS-01 cataract trial results after administrative errorJul 30Trial updateOCS-01Oculis
Bristol Myers Squibb raises 2026 guidance, cites pipeline progress across four programsJul 30Quarterly updateBristol Myers Squibbluspatercept
Nexcella registers Phase 3 NEXICART-3 trial of CAR-T NXC-201 in AL amyloidosisJul 16Trial updateImmix Biopharma, Inc.
FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myelomaJul 15Regulatory decisionisatuximabisatuximab-irfc
Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophreniaJul 7Weekly roundup, 2 itemsBristol Myers Squibbpomalidomide
Sign inSign in